SCHEMBL3865675

SCHEMBL3865675

CCOC(C)OC1(C)CCC(O[Si](CC)(CC)CC)CC(=O)OC(/C(C)=C/C=C/C(C)CC2OC2C(C)C(CC)OC(=O)N(C)C)C(C)/C=C/C1C(=O)OOc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SF3B3 Q15393 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866525 0.94 SF3B3 (0.36) SF3B3
SCHEMBL3866725 0.92 SF3B3 (0.37) SF3B3
SCHEMBL3876416 0.88 SF3B3 (0.44) SF3B3
SCHEMBL3870122 0.86 SF3B3 (0.45) SF3B3
SCHEMBL1268726 0.84 SF3B3 (0.34) SF3B3
SCHEMBL3869393 0.83 SF3B3 (0.40) SF3B3
SCHEMBL3872015 0.81 SF3B3 (0.43) SF3B3
SCHEMBL1268723 0.80 SF3B3 (0.37) SF3B3
SCHEMBL3876413 0.80 SF3B3 (0.44) SF3B3
SCHEMBL16075739 0.79 SF3B3 (0.41) SF3B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576204-B2 Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same MERCIAN CORPORATION (JP) 2009-08-18 US disclosed
US-20060235002-A1 Novel physiologically active substance EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-10-19 US disclosed
EP-1541570-A1 NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCE MERCIAN CORPORATION (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235002-A1 Novel physiologically active substance HIF1AN, HIF1A, VEGFA SF3B3 2919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.